ABUS
Arbutus Biopharma Corporation
$4.34
-0.23%
2026-05-08
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Key Fundamentals
Forward P/E
-26.11
EPS (TTM)
$-0.17
ROE
-38.5%
Revenue Growth (YoY)
-33.2%
Profit Margin
-237.9%
Debt/Equity
5.47
Price/Book
10.84
Beta
0.62
Market Cap
$849.8M
Avg Volume (10D)
2.1M
Recent Breakout Signals
No recent breakout signals detected for ABUS.
Recent Price Range (60 Days)
60D High
$4.85
60D Low
$3.85
Avg Volume
2.1M
Latest Close
$4.34
Get breakout alerts for ABUS
Sign up for Breakout Scanner to receive daily notifications when ABUS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Arbutus Biopharma Corporation (ABUS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ABUS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ABUS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.